home / stock / vera / vera news

VERA News and Press, Vera Therapeutics Inc. From 06/02/22

Stock Information
Company Name: Vera Therapeutics Inc.
Stock Symbol: VERA
Market: NASDAQ
Website: veratx.com
Menu
VERA VERA Quote VERA Short VERA News VERA Articles VERA Message Board
Get VERA Alerts

News, Short Squeeze, Breakout and More Instantly...
VERA - Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s mana...
VERA - Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress

Atacicept is the first known investigational therapy to decrease both circulatory Gd-IgA1 and anti-Gd-IgA1 autoantibodies which correlate with increased risk of IgA nephropathy disease progression New analysis shows atacicept improved renal function in patients with mild-to-mode...

VERA - Vera Therapeutics GAAP EPS of -$0.71 misses by $0.07

Vera Therapeutics press release (NASDAQ:VERA): Q1 GAAP EPS of -$0.71 misses by $0.07. Vera reported approximately $151 million in cash, cash equivalents and marketable securities as of March 31, 2022 For further details see: Vera Therapeutics GAAP EPS of -$0.71 misses by $0.07

VERA - Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis planned for 2H-2022, following positive clinical strategy meeting with FDA earlier this year Results from a ...
VERA - Vera Therapeutics to Present at Upcoming Conferences in May 2022

BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s manag...

VERA - Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association - European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

BRISBANE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced two oral presentations featuring...

VERA - Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022

BRISBANE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that interim data from the Phase...
VERA - Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors

BRISBANE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, announced today the appointment Michael M. Morrissey...

VERA - Vera Therapeutics GAAP EPS of -$0.79

Vera Therapeutics press release (NASDAQ:VERA): Q4 GAAP EPS of -$0.79. Cash and cash equivalents of $79.7M as of December 31, 2021 For further details see: Vera Therapeutics GAAP EPS of -$0.79

VERA - Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 Acquired MAU868, a first-in-class monoclonal antibody to treat BK Virus infections, full results from interim analysis of Phase 2 study of MAU868 in kidney transplant recipients planned for mid-2...
Previous 10 Next 10